Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
✨ Onyx Summary Geron Corporation announced multiple leadership changes to align with its commercial growth strategy, including the appointment of Ahmed ElNawawi as EVP and Chief Commercial Officer, alongside new senior hires in technical operations, investor relations, and portfolio management. These appointments strengthen Geron’s leadership capabilities as it drives commercialization
✨ Onyx Summary Avidity Biosciences completed a positive pre-BLA meeting with the U.S. FDA for delpacibart zotadirsen (del-zota), its investigational Duchenne muscular dystrophy (DMD44) therapy, and now plans to file the BLA in Q1 2026 to include additional CMC data. The company’s first planned BLA submission marks a key
✨ Onyx Summary Seer, Inc. announced its participation at the 2025 American Society of Human Genetics Annual Meeting, where it will showcase how its Proteograph® Product Suite enables integration of proteomics and genomics to advance precision medicine. The company will host a featured CoLab session and support multiple scientific presentations demonstrating
✨ Onyx Summary Rocket Pharmaceuticals granted inducement equity awards to newly appointed Chief Medical Officer Dr. Syed Rizvi, consisting of stock options and restricted stock units totaling approximately 729,765 shares. The awards, approved under Nasdaq’s inducement grant rule, align long-term incentives with Rocket’s strategic growth as it advances
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
✨ Onyx Summary Lexicon Pharmaceuticals hosted a policy roundtable in Washington, DC, bringing together clinicians, patient advocates, and industry experts to discuss expanding the scope of the federal “Alternatives to PAIN Act” to include chronic pain sufferers, beyond its current focus on acute and post-surgical pain. CEO Mike Exton emphasized the
✨ Onyx Summary Lexicon Pharmaceuticals convened a policy roundtable in Washington, D.C., with clinicians, advocates, and patients to discuss expanding the Alternatives to PAIN Act to include chronic pain patients under Medicare Part D coverage for non-opioid treatments. The company plans to publish a White Paper summarizing insights from the
“After just one single infusion, about a third of patients remained in remission for five years. Some physicians even called it a functional cure,” Ying Huang underlines why CARVYKTI is reshaping expectations in oncology.
✨ Onyx Summary Affinia Therapeutics closed a $40 million Series C financing led by NEA with participation from Eli Lilly and existing investors to advance its lead gene therapy candidate AFTX-201 for BAG3 dilated cardiomyopathy (DCM). The proceeds will support IND submission in Q4 2025 and initiation of the Phase 1/
“Preventative care spending fell from 14.1% to just 5.2% of Government healthcare spending.” Ben Phillips warns that welfare reforms could widen existing health gaps.
Anis Fahandej-Sadi breaks down the big problems with current incentive structures
✨ Onyx Summary Aspect Biosystems Chief Scientific Officer Sam Wadsworth will present at the 2025 Cell & Gene Meeting on the Mesa on October 7 in Phoenix, highlighting the company’s advancements in regenerative medicine. The annual conference, organized by the Alliance for Regenerative Medicine, gathers global leaders in cell and
✨ Onyx Summary Avidity Biosciences will present new one-year data on delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD44) at the 30th Annual World Muscle Society Congress, showing reversal of disease progression and improvements across functional measures from its EXPLORE44® and EXPLORE44-OLE™ trials. The presentations, featuring leading clinicians, reinforce del-zota’s
✨ Onyx Summary Phathom Pharmaceuticals appointed Sanjeev Narula as Chief Financial and Business Officer, bringing over two decades of financial leadership experience from Intra-Cellular Therapies, Viatris, and Pfizer. His appointment strengthens Phathom’s executive team as the company advances commercialization of its GI franchise, VOQUEZNA, and pursues its strategy toward profitability
"Some companies can’t even finish clinical trials because they can’t get enough material. It all comes down to the supply chain,” Thomas Eiden underscores why secure isotope access is critical for next-generation cancer treatment.
